Ongoing trials with bempegaldesleukin (NKTR-214; pegylated recombinant IL2) plus anti-PD1 (NCT02983045) continue to demonstrate well-tolerated and anti-tumor efficacy in metastatic urothelial carcinoma [424]. Here, IL2 is linked to neoplasm.